Spatial Transcriptomic and Proteomic Analysis Identifies Novel Immune-Associated Biomarkers of Anti-PD1 Response in Metastatic Melanoma.
8 affiliations
- 1Medical Immuno-Oncology Research Group, Cancer Research Unit, Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.
- 2Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.
- 3InFLAMES Research Flagship, University of Turku, Turku, Finland.
- 4Auria Biobank, Turku University Hospital, University of Turku, Turku, Finland.
- 5Department of Oncology, Turku University Hospital, Turku, Finland.
- 6Laboratory Division, Department of Pathology, Turku University Hospital, University of Turku, Turku, Finland.
- 7Cancer Research Unit, Institute of Biomedicine, FICAN West Cancer Centre Laboratories, University of Turku, Turku, Finland.
- 8Turku Bioscience Center, University of Turku, Turku, Finland.
Abstract
Resistance to anti-PD1 therapy remains a major challenge in metastatic melanoma, despite long-term benefit in some patients. Since a functional dendritic cell (DC)-CD8⁺ T cell axis is essential for anti-PD1 response, biomarkers associated with this axis may help characterize underexplored immune states linked to resistance. Here, we further characterized poor survival predictor (PSP) biomarkers previously negatively correlated with DC-CD8⁺ T cell axis in melanoma, evaluating their associations with anti-PD1 response, immune infiltration, and transcriptional and proteomic signatures. Pre-treatment transcriptomic data were analysed using CIBERSORTx and Reactome, while NanoString GeoMx spatial transcriptomic and proteomic data were used to resolve biomarker-associated features across tumour and immune compartments. We identified 28 PSP biomarkers significantly increased in non-responsive patients with strong correlations with one another, suggesting coordinated transcriptional patterns within a tumour microenvironment unfavourable to therapeutic response and survival. These biomarkers were associated with immunosuppressive cell types, decreased cytotoxicity, and pathways related to transcription, translation, epigenetic regulation, and signal transduction. Spatially, PSP biomarkers were expressed in both tumour and immune compartments, but survival associations were compartment- and site-specific. Among them, FAM57A, GSTA4 and KCTD1 were associated with poor survival when highly expressed in the CD45⁺ immune compartment of lymph node metastases. Their expression was associated with transcriptomic signatures of reduced immune activation, altered antigen presentation, and epigenetic regulation, and increased proteomic PI3K-AKT-mTORC1/MAPK signalling, especially upon co-expression. Together, these results identify FAM57A, GSTA4 and KCTD1 as emerging immune-associated biomarkers linked to established resistance-associated immune states and poor prognosis in metastatic melanoma.
Related
- Histopathology-guided spatial transcriptomic analysis identifies an ECM-associated stromal pattern in lacrimal gland adenoid cystic carcinoma with complementary proteomic and functional analyses
- Integrated analysis of transcriptomic and proteomic profiles identifies divergent regulatory networks for intramuscular fat in Chinese versus Western Pigs
- Serum Proteomic Profiling by SomaScan Aptamer Array Identifies Candidate Predictive and Monitoring Biomarkers of Distant Recurrence in Triple-Negative Breast Cancer
- Integrated transcriptomic and proteomic profiling of RXRA-overexpressing chronic myeloid leukemia cells identifies protein kinase D as a candidate target for imatinib sensitization
- Primary-Tumor Transcriptomic Signatures Associated with Circulating Tumor Cells Status in Breast Cancer: From CTC-Negative Remodeling to CTC-Associated Metastatic Programs
BibTeX
@article{koskela2026spatial,
title = {{Spatial Transcriptomic and Proteomic Analysis Identifies Novel Immune-Associated Biomarkers of Anti-PD1 Response in Metastatic Melanoma.}},
author = {S A Koskela and R E Kallionpää and I Mäkelä and E-M Birkman and M Sundvall and C R Figueiredo},
journal = {Scandinavian journal of immunology},
year = {2026},
month = oct,
doi = {10.1111/sji.70153},
url = {https://europepmc.org/article/MED/42908204},
note = {CC BY},
}
RIS
TY - JOUR
TI - Spatial Transcriptomic and Proteomic Analysis Identifies Novel Immune-Associated Biomarkers of Anti-PD1 Response in Metastatic Melanoma.
AU - S A Koskela
AU - R E Kallionpää
AU - I Mäkelä
AU - E-M Birkman
AU - M Sundvall
AU - C R Figueiredo
PY - 2026
DA - 2026/10/01
JO - Scandinavian journal of immunology
DO - 10.1111/sji.70153
UR - https://europepmc.org/article/MED/42908204
AB - Resistance to anti-PD1 therapy remains a major challenge in metastatic melanoma, despite long-term benefit in some patients. Since a functional dendritic cell (DC)-CD8⁺ T cell axis is essential for anti-PD1 response, biomarkers associated with this axis may help characterize underexplored immune states linked to resistance. Here, we further characterized poor survival predictor (PSP) biomarkers previously negatively correlated with DC-CD8⁺ T cell axis in melanoma, evaluating their associations with anti-PD1 response, immune infiltration, and transcriptional and proteomic signatures. Pre-treatment transcriptomic data were analysed using CIBERSORTx and Reactome, while NanoString GeoMx spatial transcriptomic and proteomic data were used to resolve biomarker-associated features across tumour and immune compartments. We identified 28 PSP biomarkers significantly increased in non-responsive patients with strong correlations with one another, suggesting coordinated transcriptional patterns within a tumour microenvironment unfavourable to therapeutic response and survival. These biomarkers were associated with immunosuppressive cell types, decreased cytotoxicity, and pathways related to transcription, translation, epigenetic regulation, and signal transduction. Spatially, PSP biomarkers were expressed in both tumour and immune compartments, but survival associations were compartment- and site-specific. Among them, FAM57A, GSTA4 and KCTD1 were associated with poor survival when highly expressed in the CD45⁺ immune compartment of lymph node metastases. Their expression was associated with transcriptomic signatures of reduced immune activation, altered antigen presentation, and epigenetic regulation, and increased proteomic PI3K-AKT-mTORC1/MAPK signalling, especially upon co-expression. Together, these results identify FAM57A, GSTA4 and KCTD1 as emerging immune-associated biomarkers linked to established resistance-associated immune states and poor prognosis in metastatic melanoma.
SN - 0300-9475
SN - 1365-3083
ER -